首页> 外文期刊>IDrugs: the investigational drugs journal >The future of G protein-coupled receptors as targets in drug discovery.
【24h】

The future of G protein-coupled receptors as targets in drug discovery.

机译:G蛋白偶联受体作为药物开发目标的未来。

获取原文
获取原文并翻译 | 示例
           

摘要

G protein-coupled receptors (GPCRs) represent the most abundant drug targets today. A large number of GPCR-based drugs have already been developed for a variety of indications in human disease. However, orphan receptors with unidentified ligands serve as potential targets still to be explored. Moreover, research on the interaction of GPCRs with different molecules in the signal transduction pathways, and further studies on receptor dimerization may also lead to the discovery of new drugs. Structure-based drug design will eventually play a key role in generating better and more selective drugs more rapidly when high-resolution structures of GPCRs can be provided by expression, purification and crystallography technologies.
机译:G蛋白偶联受体(GPCR)代表了当今最丰富的药物靶标。已经开发出许多基于GPCR的药物用于人类疾病的多种适应症。然而,具有未知配体的孤儿受体作为潜在的靶标尚待探索。此外,对GPCRs与不同分子在信号转导途径中相互作用的研究以及对受体二聚化的进一步研究也可能导致新药的发现。当可以通过表达,纯化和晶体学技术提供GPCR的高分辨率结构时,基于结构的药物设计最终将在更快地产生更好和更具选择性的药物中发挥关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号